Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
e-cue
- Development stage
- Unknown
- Lead developer
- Kaléo
- Administration
- Subcutaneous
01
Overview
**e-cue** is a novel epinephrine auto-injector developed by Intelliject for the emergency treatment of allergic reactions, including anaphylaxis. It delivers epinephrine, a sympathomimetic catecholamine that acts as an alpha- and beta-adrenergic agonist to rapidly reverse life-threatening symptoms by causing vasoconstriction, bronchodilation, increased cardiac output, and stabilization of mast cells to inhibit further mediator release. The device received tentative FDA approval for its NDA, indicating it met safety and efficacy standards pending final approval, likely related to manufacturing or patent exclusivity issues.[3]
- Brand names
- e-cue
02
Targets
ADRB2 (β2)ADRB1 (β1)ADRA2A (α2A)ADRA1A (α1A)
Beyond the preview
Go deeper on e-cue.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on e-cue.